The products to be developed by the company are in-licensed and own products and the larger focus is on self-researched products.
Elder Pharmaceuticals director Alok Saxena said they are looking at launching atleast 8-9 products each in the Women’s healthcare & Nutraceuticals segments which are growing at an average of 18-20% annually – higher than the 12-13% growth rate of the overall domestic pharma industry.
"Our scientists are also working on new products, new drug delivery systems and combination therapies in niche therapeutic segments like osteoporosis, dermatology, cardiology, pain management, would care, vitamin supplements etc and we hope to launch atleast 3-4 new products in each of these segments," Saxena said.
The company said remaining launches will be in-licensed products.
Elder Pharmaceuticals is also looking at the wound care & pain management segments which contribute about 16% to Elder’s turnover and anticipated to grow at over 15% every year.